Mereo Biopharma
Mereo Biopharma Group plc, commonly referred to as Mereo Biopharma, is a pioneering biopharmaceutical company headquartered in Great Britain. Founded in 2015, the company focuses on developing innovative therapies for patients with rare diseases and unmet medical needs, particularly in the fields of oncology and metabolic disorders. Mereo Biopharma's core products, including its unique therapeutic candidates, are designed to address significant gaps in current treatment options, showcasing the company's commitment to advancing healthcare. With a strong emphasis on clinical development, Mereo has achieved notable milestones, including successful clinical trials that position it as a key player in the biopharma industry. As it continues to expand its operational reach, Mereo Biopharma is dedicated to delivering transformative solutions that enhance patient outcomes and solidify its market presence.
DitchCarbon Score
How does Mereo Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mereo Biopharma's score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Mereo Biopharma's reported carbon emissions
In 2022, Mereo Biopharma reported approximately 460 kg CO2e per employee, reflecting a continued commitment to reducing its carbon footprint. This figure shows a decrease from about 490 kg CO2e per employee in 2021 and 730 kg CO2e per employee in 2020, indicating a positive trend in emissions management. While specific Scope 1, 2, and 3 emissions data have not been disclosed, the company has not set formal reduction targets or climate pledges as per the available information. Mereo Biopharma's focus on minimising emissions aligns with industry standards for climate responsibility, although further transparency regarding their overall emissions and reduction strategies would enhance their commitment to sustainability. As a UK-based organisation, Mereo Biopharma is positioned to contribute to broader climate goals, and its ongoing efforts to lower emissions per employee demonstrate a proactive approach to environmental stewardship.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mereo Biopharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
